6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I

1. A compound represented by the structural Formula I:

or a pharmaceutically acceptable salt of said compound, wherein:

R 1 represents phenyl, naphthyl, benzyl, stryryl, furanyl, thienyl, pyrazolyl, pyridyl, oxazolyl, benzothienyl or benzooxadiazolyl, each of which is optionally substituted by one or more substituents selected from the group consisting of alkyl, halogen, alkoxy, alkylcarbonyl, alkylsulphonyl, cyano, nitro, aryl, heteroaryl, aryloxy, carboxyl, alkoxycarbonylalkyl, cycloalkyl and morpholino; and

R 2 -R 4 independently represent alkyl;

with the exception of those compounds wherein:

R 2 -R 4 each represent methyl; and

R 1 represents phenyl substituted by substituted alkoxycarbonyl, substituted alkylcarbonyloxy, substituted sulfonylamino, substituted carbonylamino, or unsubstituted or substituted aminocarbonyl;

and excluding the following compounds:

1,3,3-trimethyl-6-[(phenylmethyl)sulphonyl]-6-azabicyclo[3.2.1]octane;

6-[(3,4-difluorophenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

6-[(4-aminophenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

1,3,3-trimethyl-6-[[4-(5-phenyl-2-oxazolyl)phenyl]sulfonyl]-6-azabicyclo[3.2.1]octane;

6-[(2-methyl-5-tert-butylphenyl)sulfonyl]-6-azabicyclo[3.2.1]octane;

6-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

6-[[5-2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenoxy]-2-hydroxyphenyl]sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

1,3,3-trimethyl-6-[[5-[2-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]-4-pyrimidinyl]-2-thienyl]sulfonyl]-6-azabicyclo[3.2.1]octane;

6-[(4-ethoxyphenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

1,3,3-trimethyl-6-[[2-(trifluoromethyl)phenyl]sulfonyl]-6-azabicyclo[3.2.1]octane;

6-[(2,3-dichlorophenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

3-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)sulfonyl]benzoic acid;

3-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)sulfonyl]benzoic acid methyl ester;

1,3,3-trimethyl-6-[(3-nitrophenyl)sulfonyl]-6-azabicyclo[3.2.1]octane;

4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)sulfonyl]benzoic acid;

1,3,3-trimethyl-6-[(2,3,5,6-tetramethylphenyl)sulfonyl]-6-azabicyclo[3.2.1]octane;

1,3,3-trimethyl-6-[(2-nitrophenyl)sulfonyl]-6-azabicyclo[3.2.1]octane;

6-[(4-acetylphenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

6-[(2,5-dimethylphenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

6-[(4-methoxyphenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

6-[(5-bromo-2-ethoxyphenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

6-[(2,5-dibromophenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

6-[(2,4-difluorophenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

6-[(5-bromo-6-chloro-3-pyridinyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

6-[(2,5-dichlorophenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane;

1,3,3-trimethyl-6-phenylsulfonyl-6-azabicyclo[3.2.1]octane;

6-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octan-6-ylsulfonyl)benzo[d]oxazol-2(3H)-one;

6-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octan-6-ylsulfonyl)benzo[cd]indol-2(1H)-one;

3-((1R,5S)-1,3,3-trimethyl-6-azabicyclo[3.2.1]octan-6-ylsulfonyl)-1H-pyrazolo[3,4-b]pyridine;

2,2,2-trifluoro-1-(8-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octan-6-ylsulfonyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethanone;

6-[(4-tert-butylphenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane; and

6-[(3-aminophenyl)sulfonyl]-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane.

2. A compound selected from the group consisting of:

an enantiomer thereof or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, adjuvant or vehicle.

4. A pharmaceutical composition comprising at least one compound of claim 2 , an enantiomer thereof or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, adjuvant or vehicle.